Form 8-K - Current report:
SEC Accession No. 0001628280-25-015759
Filing Date
2025-04-01
Accepted
2025-04-01 08:26:39
Documents
18
Period of Report
2025-04-01
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20250401.htm   iXBRL 8-K 28437
2 EX-99.1 aquestiveannouncesndasub.htm EX-99.1 14181
6 aquestiveannouncesndasub001.jpg GRAPHIC 225418
7 aquestiveannouncesndasub002.jpg GRAPHIC 177186
8 aquestiveannouncesndasub003.jpg GRAPHIC 318491
9 aquestiveannouncesndasub004.jpg GRAPHIC 304843
  Complete submission text file 0001628280-25-015759.txt   1585512

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20250401.xsd EX-101.SCH 1776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20250401_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20250401_pre.xml EX-101.PRE 12504
20 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20250401_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 25796756
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)